Martine Rothblatt, who serves as chairperson and chief executive officer of United Therapeutics Corporation (NASDAQ: UTHR), sold company common stock valued at about $5.1 million on March 25, 2026. The disposition was executed across multiple trades with execution prices ranging from $536.97 to $548.5237.
On the same day that the sales occurred, Rothblatt exercised stock options covering 9,500 shares at an exercise price of $146.03, resulting in the acquisition of shares with an aggregate intrinsic value of $1,387,285. The purchases and sales were transacted under a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025.
Following these transactions, Rothblatt's direct holding in United Therapeutics stands at 40,513 shares. The filing also notes that Rothblatt retains additional indirect ownership through various family trusts.
Data from InvestingPro cited in company disclosures indicates management has been an active buyer of stock, a detail highlighted among the platform's set of investment observations. The platform also offers a dedicated Pro Research Report covering United Therapeutics, though access to that report requires a subscription.
Corporate capital allocation and program details
United Therapeutics has announced a formal $2 billion stock repurchase program that was approved by its board of directors. The buyback framework includes accelerated share repurchase (ASR) agreements totaling $1.5 billion with Citibank, and an additional $500 million that the company may use for future repurchases at its discretion.
The simultaneous occurrence of significant insider activity and a large, board-approved buyback program represents a notable moment in the company's capital allocation profile. The ASR component with Citibank provides an immediate mechanism to retire shares while the discretionary tranche offers flexibility for further repurchase activity.
Clinical and analyst developments
On the clinical front, results from United Therapeutics' phase 3 TETON-2 study were published in the New England Journal of Medicine. The trial showed that nebulized Tyvaso produced a statistically significant improvement in forced vital capacity compared with placebo over a 52-week period in patients with idiopathic pulmonary fibrosis, meeting the study's primary endpoint.
Analyst coverage has reacted to these developments. Cantor Fitzgerald increased its price target for United Therapeutics to $625 while maintaining an Overweight rating, citing favorable expectations related to the company’s TETON-1 trial. TD Cowen reaffirmed a Buy rating with a $575 price target.
What is known and what remains unchanged
The sequence of transactions and corporate announcements reported here are factual and documented: Rothblatt's sales and option exercise on March 25, 2026; the 10b5-1 plan adoption on November 7, 2025; the company-approved $2 billion repurchase program with $1.5 billion in ASR agreements with Citibank and $500 million available for discretionary repurchases; publication of TETON-2 phase 3 results in the New England Journal of Medicine; and analyst actions from Cantor Fitzgerald and TD Cowen with the price targets and ratings stated above.
Investors seeking additional, subscription-based research and aggregated signals may consult the Pro Research Report and InvestingPro indicators referenced in company materials.